Hyperbaric oxygen therapy addresses the retinal hypoxia and oxidative stress driving macular degeneration
Hyperbaric oxygen therapy addresses the retinal hypoxia and oxidative stress driving macular degeneration
Understanding macular degeneration and how HBOT addresses retinal hypoxia and oxidative stress
Age-related macular degeneration (AMD) is the leading cause of central vision loss in adults over 50, affecting approximately 20 million Americans. It involves the progressive degeneration of the macula — the central region of the retina responsible for sharp, detailed vision needed for reading, driving and recognizing faces — ultimately causing central vision loss and legal blindness in severe cases.
AMD presents in two forms. Dry AMD, the more common form, involves the gradual accumulation of drusen deposits beneath the retinal pigment epithelium (RPE), with progressive RPE atrophy and photoreceptor loss. Wet AMD, the more rapidly progressive form, involves abnormal blood vessel growth (choroidal neovascularization) beneath the macula, which can cause acute, severe vision loss through bleeding and leakage.
The pathophysiology of AMD centers on the chronic hypoxia and oxidative stress that develop as choroidal blood flow to the outer retina deteriorates with aging. This hypoxia impairs RPE cell function — disrupting the clearance of photoreceptor metabolic waste and driving drusen accumulation — and creates an oxidatively stressed environment that promotes photoreceptor degeneration. HBOT addresses this by delivering concentrated oxygen to hypoxic macular tissue and upregulating the antioxidant defenses that protect surviving RPE cells and photoreceptors from oxidative damage.
Blurred or distorted central vision (straight lines appearing wavy on Amsler grid)
Dark spot or "blind spot" in the center of the visual field
Difficulty reading, recognizing faces and seeing fine detail
Reduced contrast sensitivity and difficulty in low light
Progressive central vision loss leading to legal blindness in advanced cases
Sudden severe central vision loss in wet AMD from neovascular bleeding
How HBOT protects the macula from progressive degeneration
AMD kills macular cells through a combination of hypoxia, oxidative stress and RPE dysfunction. HBOT addresses all three simultaneously, offering a metabolic defense for surviving macular tissue.
Increases oxygen delivery to the hypoxic outer retina and macula
Slows drusen accumulation and RPE degeneration
Improves visual acuity and contrast sensitivity
Reduces oxidative stress in retinal tissue
Activates neuroprotective mechanisms for remaining photoreceptors
Complements anti-VEGF therapy in wet AMD
For Providers
Clinical evidence for HBOT in macular degeneration
HBOT for AMD is supported by controlled clinical trials and case series, with the most comprehensive evidence coming from work by Bojic and Gottlieb.
Bojic et al. — controlled clinical trial (1993, 2001): Ljuba Bojic and colleagues in Split, Croatia conducted the most systematic series of HBOT trials in AMD patients. Their 1993 prospective study demonstrated significant improvements in visual acuity and reductions in drusen size in dry AMD patients treated with HBOT compared to controls. The 2001 follow-up study confirmed that annual maintenance HBOT courses sustained visual acuity improvements over multiple years of follow-up, providing the most compelling long-term data for HBOT in AMD. [Bojic L et al. Graefes Arch Clin Exp Ophthalmol. 1993;231(6):347–352. PMID: 8325516; Bojic L et al. Undersea Hyperb Med. 2001;28(2):71–74. PMID: 12002312]
Gottlieb et al. — prospective pilot study (2002): Gottlieb and colleagues published a prospective pilot study of HBOT in AMD patients demonstrating improvements in best-corrected visual acuity and contrast sensitivity following treatment, with HBOT well-tolerated across a range of AMD severities. The study supported the mechanistic rationale for HBOT in AMD and provided clinical data supporting further investigation. [Gottlieb JL et al. Retina. 2002;22(5):536–541. PMID: 12441719]
Retinal oxygenation mechanism: The fundamental mechanism for HBOT in AMD is well-established in retinal physiology. Choroidal blood flow to the outer retina declines progressively in AMD, creating macular hypoxia. HBOT raises arterial oxygen content dramatically, enabling dissolved oxygen to diffuse into hypoxic macular tissue via plasma diffusion independent of the compromised choroidal circulation. This mechanism directly addresses the primary cellular stress driving RPE and photoreceptor degeneration.
Antioxidant upregulation: Oxidative stress is a central mechanism of RPE and photoreceptor cell death in AMD. HBOT at therapeutic pressures upregulates superoxide dismutase and catalase — the primary endogenous antioxidant enzymes — providing a cellular defense against the oxidative damage that drives AMD progression. This antioxidant effect is well-documented across multiple HBOT applications and is mechanistically relevant to AMD pathophysiology.
Our AMD HBOT protocol at Bay Area Hyperbarics
HBOT for AMD targets the retinal hypoxia and oxidative stress underlying macular cell death. It works best as part of a comprehensive AMD management plan in coordination with your ophthalmologist or retinal specialist.
Ophthalmological assessment and baseline vision testing
Our medical team coordinates with your ophthalmologist to review your current AMD classification (dry vs. wet, early vs. advanced), visual acuity measurements, OCT imaging and drusen burden. Baseline visual function testing before treatment enables accurate monitoring of your response to HBOT.
HBOT sessions to restore macular oxygenation and reduce oxidative stress
You breathe 100% oxygen at 2.0 to 2.4 atmospheres absolute for approximately 90 minutes per session. AMD protocols typically involve 30 to 40 sessions as an initial course, with visual function assessment at completion. Periodic maintenance courses — typically annually — help sustain the oxygenation benefits over the long term.
Visual monitoring and long-term maintenance planning
We track visual acuity, contrast sensitivity and Amsler grid performance throughout and after treatment. For wet AMD patients, we coordinate with your retinal specialist to integrate HBOT with ongoing anti-VEGF management. Maintenance HBOT courses are planned based on your visual response and AMD progression rate.
Frequently Asked Questions
Answers to the questions AMD patients most often ask about hyperbaric oxygen therapy.
HBOT does not reverse the AMD process or regenerate photoreceptors that have already been lost. It works by improving the metabolic environment for surviving macular cells — restoring oxygen delivery and reducing oxidative stress — which can slow progression and, in some patients, improve visual function in areas of viable but metabolically impaired tissue. Clinical studies have reported measurable visual acuity improvements in treated patients. We discuss realistic expectations based on your AMD classification and disease severity at your consultation.
Losing vision from AMD? Ask us about HBOT
Bay Area Hyperbarics offers HBOT as a supportive therapy for AMD patients seeking to preserve remaining vision and slow disease progression. Call us to schedule a consultation and discuss whether HBOT is appropriate for your stage of disease.
